Kirk L Kinard, DO | |
2215 Jefferson Davis Dr, Oxford, MS 38655-5221 | |
(662) 638-0462 | |
(866) 658-0083 |
Full Name | Kirk L Kinard |
---|---|
Gender | Male |
Speciality | |
Experience | Years |
Location | 2215 Jefferson Davis Dr, Oxford, Mississippi |
Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1376740803 | NPI | - | NPPES |
02339383 | Medicaid | MS | |
1522852 | Medicaid | TN |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
208VP0014X | Pain Medicine - Interventional Pain Medicine | 19491 (Mississippi) | Primary |
208VP0014X | Pain Medicine - Interventional Pain Medicine | 2200 (Tennessee) | Secondary |
Mailing Address | Practice Location Address |
---|---|
Kirk L Kinard, DO 716 Mogridge Ln, Oxford, MS 38655-5150 Ph: () - | Kirk L Kinard, DO 2215 Jefferson Davis Dr, Oxford, MS 38655-5221 Ph: (662) 638-0462 |
News Archive
The Government has "got it wrong" when it comes to listening to the recommendations of its National Screening Committee regarding the implementation of a UK cardiac screening programme for your young people.
One of the most common types of brain tumors in adults, glioblastoma multiforme, is one of the most devastating. Even with recent advances in surgery, radiation and chemotherapy, the aggressive and invasive tumors become resistant to treatment, and median survival of patients is only about 15 months. In a study published in Neuro-Oncology, researchers at Mayo Clinic identify an important association between the naturally occurring enzyme Kallikrein 6, also known as KLK6, and the malignant tumors.
Robotic RPLND utilizes laparoscopy combined with robotic technology to perform dissection and removal of lymph node tissue in the retroperitoneum both as a staging as well as therapeutic procedure for patients with testicular cancer.
ImmunoCellular Therapeutics, Ltd. announced that updated efficacy and safety data from the phase II trial of dendritic cell-based immunotherapeutic vaccine ICT-107 in patients with newly diagnosed glioblastoma multiforme (GBM) were presented at the 2014 American Society for Clinical Oncology (ASCO) annual meeting in Chicago.
To meet the needs of employers challenged with offering competitive yet cost-effective employee benefits, leading benefits administrator EBS-RMSCO, Inc. has developed diversified, integrated services. The company added to their set of services web-based data integration, analysis and reporting solutions from Benefit Informatics to enhance service delivery.
› Verified 9 days ago